Trial reportTechnology in cancer research & treatment2018
First Human Trial of High-Frequency Irreversible Electroporation Therapy for Prostate Cancer.
Trial report in Technology in cancer research & treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 79 citations in OpenAlex.
- Electricity-Based Locoregional Cancer Therapies and Their Associated Drug Delivery Technologies: From Principles of Action to Clinical Implications.Biomaterials research · 2026Review
- Compound steep-pulse irreversible electroporation for prostate ablation in Beagle dogs: parameter evaluation and short-term safety.Frontiers in urology · 2026Article
- High-intensity irreversible electroporation targeting intracellular structures enhance tumor ablation in lung cancer models.PloS one · 2026Article
- Pulsed field ablation in medicine: irreversible electroporation and electropermeabilization theory and applications.Radiology and oncology · 2025Review
- Advances in irreversible electroporation for prostate cancer.Discover oncology · 2024Review
- Current focal therapies for the treatment of low- and intermediate-risk prostate cancer.Asian journal of andrology · 2024Article
- The equivalence of different types of electric pulses for electrochemotherapy with cisplatin - anRadiology and oncology · 2024Article
- Ultrasound-guided percutaneous high-frequency irreversible electroporation in porcine livers using four electrode needles: A feasibility and safety study.Cancer medicine · 2024Article
- Scheduled dosage regimen by irreversible electroporation of loaded erythrocytes for cancer treatment.APL bioengineering · 2023Article
- Review
- Effects of different applied voltages of irreversible electroporation on prostate cancer in a mouse model.Scientific reports · 2022Article
- Boosting the Immune Response-Combining Local and Immune Therapy for Prostate Cancer Treatment.Cells · 2022Review
- Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial.JAMA surgery · 2022Article
- Article
- High-frequency irreversible electroporation brain tumor ablation: exploring the dynamics of cell death and recovery.Bioelectrochemistry (Amsterdam, Netherlands) · 2022Article
- Invasive and non-invasive electrodes for successful drug and gene delivery in electroporation-based treatments.Frontiers in bioengineering and biotechnology · 2022Review
- Electrotherapies for Glioblastoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Irreversible Electroporation Enhanced by Radiofrequency Ablation: An In Vitro and Computational Study in a 3D Liver Tumor Model.Annals of biomedical engineering · 2021Article
- A Theoretical Argument for Extended Interpulse Delays in Therapeutic High-Frequency Irreversible Electroporation Treatments.IEEE transactions on bio-medical engineering · 2021Article
- Irreversible Electroporation for Prostate Cancer.Life (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irreversible electroporation, as a nonthermal therapy of prostate cancer, has been used in clinic for several years. The mechanism of irreversible electroporation ablation is thermal independent; thus, the main structures (eg, rectum, urethra, and neurovascular bundle) in prostate are spared during the treatment, which leads to the retention of prostate function. However, various clinical trials have shown that muscle contractions occur during this therapy, which warrants deep muscle anesthesia. Use of high-frequency bipolar pulses has been proposed to reduce muscle contractions during treatment, which has already triggered a multitude of studies at the cellular and animal scale. In this study, we first investigated the efficacy and safety of high-frequency bipolar pulses in human prostate cancer ablation. There are 40 male patients with prostate cancer aged between 51 and 85 years involved in this study. All patients received 250 high-frequency bipolar pulse bursts with the repeat frequency of 1 Hz. Each burst comprised 20 individual pulses of 5 microseconds, so one burst total energized time was 100 microseconds. The number of the electrodes ranged 2 to 6, depending on tumor size. A small amount of muscle relaxant was still needed, so there were no visible muscle contractions during the pulse delivery process. Four weeks after treatment, it was found that the ablation margins were distinct in magnetic resonance imaging scans, and the prostate capsule and urethra were retained. Eight patients underwent radical prostatectomy for pathological analysis after treatment, and the results of hematoxylin and eosin staining revealed that the urethra and major vasculature in prostate have been preserved. By overlaying the electric field contour on the ablation zone, the electric field lethality threshold is determined to be 522 ± 74 V/cm. This study is the first to validate the feasibility of tumor ablation by high-frequency bipolar pulses and provide valuable experience of irreversible electroporation in clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.